By admin 
AstraZeneca and Amgen have announced a significant clinical triumph for their co-developed biologic, Tezspire (tezepelumab), with the drug successfully meeting all primary and key secondary endpoints in a late-stage trial for eosinophilic esophagitis (EoE). This pivotal achievement positions Tezspire for a potential third approved indication, opening a substantial new market opportunity and bolstering its trajectory towards blockbuster status. The positive results, detailed in a joint statement on Thursday, August 27, 2026, underscore Tezspire’s broad anti-inflammatory potential and its growing importance within the therapeutic arsenals of both pharmaceutical giants.
Clinical Trial Highlights: A Deeper Look into the CROSSING Study
The Phase 3 "CROSSING" trial, designed to evaluate the efficacy and safety of Tezspire in adolescents and adults with eosinophilic esophagitis, demonstrated "statistically significant and clinically meaningful improvements" across all its main and secondary objectives. While specific quantitative data were not immediately released, the companies indicated that these improvements were observed at the 24-week mark and, crucially, sustained throughout a full year of treatment. This long-term efficacy is particularly vital for chronic conditions like EoE, where sustained symptom control and disease modification are paramount.
Industry experts anticipate that the primary endpoints of the CROSSING trial likely focused on a combination of histological remission and significant improvement in dysphagia (difficulty swallowing), a hallmark symptom of EoE. Histological remission typically refers to the reduction of esophageal eosinophil counts below a certain threshold (e.g., <15 eosinophils per high-power field), a key measure of disease activity. Secondary endpoints would likely have included patient-reported outcome measures (PROMs) assessing quality of life, frequency and severity of other symptoms like food impaction or chest pain, endoscopic findings (e.g., furrows, rings, exudates), and potentially markers of inflammation. The announcement suggests that Tezspire not only achieved biological control of the disease but also translated into tangible, positive impacts on patients’ daily lives. The safety profile of Tezspire in the EoE trial is also expected to be consistent with its established profile from trials in asthma and chronic rhinosinusitis, which has generally been favorable. The full data from the CROSSING study are slated for presentation at an upcoming major medical meeting, likely a gastroenterology or allergy conference, where clinicians and researchers will eagerly await the detailed findings.
Understanding Eosinophilic Esophagitis: A Chronic, Debilitating Condition
Eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory disease of the esophagus, characterized by a dense infiltration of eosinophils in the esophageal lining. This allergic reaction leads to inflammation, fibrosis, and impaired esophageal function. Affecting an estimated more than 470,000 people in the U.S. alone, EoE’s prevalence has been steadily increasing globally, making it a significant public health concern. The condition can manifest at any age, from infancy through adulthood, and is often associated with other atopic diseases such as asthma, allergies, and eczema.
The primary symptom of EoE is dysphagia, which can range from mild difficulty swallowing to severe food impactions requiring emergency endoscopic removal. Other symptoms include chest pain, abdominal pain, reflux-like symptoms unresponsive to standard acid suppressants, and failure to thrive in children. The diagnostic process typically involves endoscopy with biopsies from different parts of the esophagus to confirm the presence and density of eosinophils. Living with EoE can severely impact a patient’s quality of life, leading to dietary restrictions, anxiety around eating, and a constant fear of food impaction.
Current treatment strategies for EoE primarily involve proton pump inhibitors (PPIs), swallowed topical corticosteroids (e.g., fluticasone, budesonide), and dietary elimination therapies (e.g., six-food elimination diet). While these treatments can be effective for some, a significant proportion of patients – approximately half, according to AstraZeneca – either do not respond adequately to initial therapies or experience relapses, highlighting a substantial unmet medical need for more targeted and durable treatment options. The chronic nature of EoE often necessitates long-term management, making the sustainability of treatment effects a critical consideration.
Tezspire’s Mechanism and Established Success in Inflammatory Diseases
Tezspire is a first-in-class human monoclonal antibody that targets and blocks the activity of thymic stromal lymphopoietin (TSLP), an epithelial-derived cytokine that plays a crucial role as an "upstream" initiator of multiple inflammatory pathways. TSLP is released by epithelial cells in response to various triggers, including allergens, viruses, and irritants, and subsequently drives the release of downstream cytokines like IL-4, IL-5, and IL-13, which are central to type 2 inflammation. By blocking TSLP at an earlier stage in the inflammatory cascade, Tezspire aims to inhibit the initiation and perpetuation of inflammation, offering a broad anti-inflammatory effect. This upstream mechanism of action distinguishes Tezspire from other biologics that target specific downstream cytokines.
Tezspire has already established itself as an important therapeutic option for patients with severe inflammatory conditions. It received its initial approval for severe asthma in December 2021, becoming the first and only biologic approved for severe asthma without phenotypic limitations, meaning it is effective regardless of a patient’s eosinophilic phenotype or other biomarkers. This broad applicability has been a key driver of its success in the asthma market. More recently, in 2025, Tezspire secured its second indication for chronic rhinosinusitis with nasal polyps (CRSwNP), another complex inflammatory condition characterized by type 2 inflammation. The success in CRSwNP further validated the broad potential of TSLP blockade across different atopic diseases.
The financial performance of Tezspire reflects its clinical impact. In 2025, both Amgen and AstraZeneca each reported over $1 billion in Tezspire sales, underscoring its rapid uptake and market penetration. AstraZeneca, which holds commercialization rights outside the U.S., reported $390 million in Tezspire sales in the second quarter of 2026 alone, representing a robust 45% increase compared to the same period in the previous year. Amgen, responsible for U.S. commercialization, has also seen significant growth. The co-development and commercialization agreement sees Amgen booking sales in the U.S., while AstraZeneca records sales in the rest of the world, with profits and costs generally shared. The consistent growth trajectory demonstrates the high demand for effective treatments in these chronic inflammatory conditions and sets a strong precedent for its potential success in EoE.
Market Opportunity and Financial Projections for EoE
The successful trial in EoE represents a significant expansion opportunity, with analysts widely characterizing it as having "blockbuster potential." William Blair analyst Matt Phipps highlighted the growing prevalence of EoE, with over 470,000 affected individuals in the U.S., as a key factor supporting this assessment. Given the high rate of non-response to conventional therapies and the chronic, debilitating nature of EoE, there is a clear demand for innovative, disease-modifying treatments. The annual market for EoE therapeutics, once fully established with biologics, could reach several billion dollars globally, making it an attractive target for pharmaceutical companies.
An expanded approval for Tezspire in EoE would not only address a significant unmet medical need but also substantially boost the revenue streams for both AstraZeneca and Amgen. Analysts are already recalibrating their peak sales estimates for Tezspire, with some projections now exceeding $5 billion annually across all indications. The addition of EoE is expected to contribute a meaningful share to this growth, leveraging Tezspire’s established brand recognition and sales infrastructure. For AstraZeneca, this development aligns perfectly with its ambitious corporate goal of achieving $80 billion in annual sales by 2030. Each successful pipeline expansion for key growth drivers like Tezspire brings the company closer to this strategic objective. Similarly, for Amgen, Tezspire is a critical component of its growth strategy, complementing other key products like the C5 complement inhibitor Uplizna (e.g., for neuromyelitis optica spectrum disorder), the T-cell engager Imdelltra (tarlatamab) for small cell lung cancer, and the PCSK9 inhibitor Repatha (evolocumab) for hyperlipidemia. This diversified portfolio aims to support sustained revenue growth, particularly as the company awaits crucial readouts from its promising obesity drug pipeline next year.
Competitive Landscape: Tezspire vs. Dupixent
Should Tezspire gain regulatory approval for EoE, it will enter a competitive market, notably facing Sanofi and Regeneron’s Dupixent (dupilumab). Dupixent, an anti-inflammatory medicine that targets the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, is already approved for a broad range of type 2 inflammatory conditions, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and specifically for eosinophilic esophagitis. Dupixent’s approval in EoE in 2022 made it the first biologic treatment specifically indicated for the condition, giving it an early mover advantage and significant market share. Regeneron and Sanofi have consistently highlighted EoE as a "meaningful growth driver" for Dupixent, emphasizing its significant sales potential within this indication.
The competition between Tezspire and Dupixent in EoE will be a fascinating dynamic to watch. While both drugs address type 2 inflammation, their mechanisms of action differ: Tezspire targets the upstream cytokine TSLP, whereas Dupixent targets IL-4 and IL-13, which are downstream mediators. This mechanistic difference could potentially translate into varying patient responses or suitability for specific EoE phenotypes. Tezspire’s broader applicability across asthma phenotypes (regardless of eosinophil counts) suggests it might also offer a broad benefit in EoE. Clinicians will carefully evaluate the detailed efficacy and safety profiles of both drugs once Tezspire’s full data are available, considering factors such as rapidity of onset, sustainability of effect, convenience of administration, and potential for combination therapies or sequential treatment approaches. The introduction of a second highly effective biologic option is ultimately beneficial for patients, providing more choices and potentially driving further innovation in the EoE treatment landscape.
Regulatory Pathway and Future Outlook
Following the successful completion of the CROSSING trial, AstraZeneca and Amgen have confirmed their intention to share these results with regulatory authorities worldwide. This typically involves submitting a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and similar applications to the European Medicines Agency (EMA) and other global regulatory bodies. Given the significant unmet need in EoE, and if the data are compelling, regulatory agencies may grant an expedited review. A typical review process for a sBLA in the U.S. can take between six to ten months, suggesting a potential approval decision in late 2027 or early 2028, assuming a standard review timeline.
Beyond regulatory submissions, the companies have committed to presenting the detailed clinical data at an upcoming major medical meeting. This public disclosure will be crucial for physicians, researchers, and patients to understand the full scope of Tezspire’s benefits and risks in EoE. Such presentations often include subgroup analyses, which could identify specific patient populations that respond particularly well to Tezspire, further informing clinical practice.
The success of Tezspire in EoE marks a pivotal moment for both AstraZeneca and Amgen, reinforcing their leadership in inflammatory and respiratory diseases. For patients suffering from this chronic and often debilitating condition, it offers renewed hope for a targeted, effective, and sustained treatment option. The biopharmaceutical industry continues its relentless pursuit of innovative therapies, and Tezspire’s expansion into EoE stands as a testament to the power of precision medicine in addressing complex, immune-mediated diseases.
